BioArctic AB (LTS:0RV2) EPS (Basic): kr2.41 (TTM As of Mar. 2026)


LTS:0RV2 BioArctic AB LTS:0RV2
78 GF Score
Price kr306.50
GF Value kr480.85
Valuation Significantly Undervalued
! 2 Warning Signs
View Full Analysis

What is BioArctic AB EPS (Basic)?

BioArctic AB LTS:0RV2 -1.35% 78 EPS (Basic) is kr2.41 as of Mar. 2026. GuruFocus rates LTS:0RV2 with a GF Score™ of 78/100 and a GF Value™ of kr480.85 (Significantly Undervalued). The stock has 2 warning signs investors should review.

BioArctic AB's basic earnings per share (Basic EPS) for the three months ended in Mar. 2026 was kr2.40. Its basic earnings per share (Basic EPS) for the trailing twelve months (TTM) ended in Mar. 2026 was kr2.41.

BioArctic AB's EPS (Diluted) for the three months ended in Mar. 2026 was kr2.39. Its EPS (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 was kr2.40.

BioArctic AB's EPS without NRI for the three months ended in Mar. 2026 was kr2.39. Its EPS without NRIearnings per share without non-recurring items for the trailing twelve months (TTM) ended in Mar. 2026 was 2.40.

During the past 12 months, BioArctic AB's average EPS without NRIGrowth Rate was -76.40% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using EPS without NRI data.

During the past 11 years, BioArctic AB's highest 3-Year average EPS without NRI Growth Rate was 368.90% per year. The lowest was -13.70% per year. And the median was 15.20% per year.

BioArctic AB  (LTS:0RV2) EPS (Basic) Explanation

EPS is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.

Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.

BioArctic AB EPS (Basic) Related Terms

BioArctic AB EPS (Basic) Historical Data

* Premium members only.

The historical data trend for BioArctic AB's EPS (Basic) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

BioArctic AB EPS (Basic) Chart

BioArctic AB Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
EPS (Basic)
Get a 7-Day Free Trial Premium Member Only Premium Member Only -1.36 -0.13 2.60 -2.00 11.55

BioArctic AB Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
EPS (Basic) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 11.55 1.09 -0.98 -0.10 2.40
LTS:0RV2
78GF Score
BioArctic AB LTS:0RV2
EPS (Basic) is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

BioArctic AB EPS (Basic) Calculation

EPS (Basic) is a rough measurement of the amount of a company's profit that can be allocated to one share of its stock. Basic earnings per share (EPS) do not factor in the dilutive effects on convertible securities.

BioArctic AB's Basic EPS for the fiscal year that ended in Dec. 2025 is calculated as

Basic EPS (A: Dec. 2025 )=(Net Income-Preferred Dividends)/Shares Outstanding (Basic Average)
=(1022.324-0)/88.546
=11.55

BioArctic AB's Basic EPS for the quarter that ended in Mar. 2026 is calculated as

Basic EPS (Q: Mar. 2026 )=(Net Income-Preferred Dividends)/Shares Outstanding (Basic Average)
=(212.391-0)/88.641
=2.40

EPS (Basic) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was kr2.41

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EPS (Basic) →
What does a EPS (Basic) of kr2.41 mean?
BioArctic AB (LTS:0RV2) has a EPS (Basic) of kr2.41 as of Mar. 2026. Earnings per share (basic) equals net income divided by the standard, non-diluted average shares outstanding. View historical data on BioArctic AB and its competitors.
Is BioArctic AB's EPS (Basic) too high?
BioArctic AB's current EPS (Basic) is kr2.41. Overall, BioArctic AB has a GF Score™ of 78/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does BioArctic AB's EPS (Basic) compare to VRTX and REGN?
BioArctic AB's EPS (Basic) of kr2.41 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EPS (Basic) for a Biotechnology company?
A good EPS (Basic) depends on the Biotechnology industry context. However, EPS (Basic) should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EPS (Basic) mean?
A high EPS (Basic) can signal that a stock is expensive relative to its fundamentals. Earnings per share (basic) equals net income divided by the standard, non-diluted average shares outstanding. View historical data on BioArctic AB and its competitors. BioArctic AB's current EPS (Basic) is kr2.41. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BioArctic AB stock overvalued right now?
Based on GuruFocus' analysis, BioArctic AB (LTS:0RV2) is currently considered Significantly Undervalued. The stock's GF Value™ is kr480.85, compared to a current price of kr306.50 — trading 36.3% below its estimated fair value. The current EPS (Basic) is kr2.41. BioArctic AB's overall GF Score™ is 78/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EPS (Basic) calculated?
EPS (Basic) is calculated from a company's financial statements. For BioArctic AB (LTS:0RV2), the current EPS (Basic) is kr2.41 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is BioArctic AB (LTS:0RV2) Overvalued in 2026?

Based on GuruFocus' analysis, BioArctic AB stock appears to be undervalued. The current stock price of kr306.50 is trading 36.3% below its estimated GF Value™ of kr480.85. GuruFocus considers BioArctic AB to be Significantly Undervalued.

Key valuation signals for LTS:0RV2:

  • EPS (Basic): kr2.41
  • GF Value™: kr480.85 vs. price of kr306.50 (36.3% below fair value)
  • GF Score™: 78/100 with 2 warning signs

No single metric tells the full story. See the LTS:0RV2 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

BioArctic AB Business Description

Address Warfvinges vag 35, Stockholm, SWE, SE-112 51
BioArctic AB is a research-based biopharmaceutical company focusing on disease-modifying treatments and diagnostics for neurodegenerative diseases, such as Alzheimer's disease and Parkinson's disease, and ALS. Geographically, it derives a majority of its revenue from North America.
78GF Score

Get the complete analysis for LTS:0RV2

EPS (Basic) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

kr306.50
Price
kr480.85
GF Value